Portal de Periódicos da CAPES

Revisão Produção Nacional Revisado por pares

BIBTEX RIS

Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis

2024; Elsevier BV; Volume: 196; Linguagem: Inglês

10.1016/j.critrevonc.2024.104321

1879-0461

Fernando Sabino Marques Monteiro, Andrey Soares, Veronica Mollica, Caio A. Leite, André Paternò Castello Dias Carneiro, Alessandro Rizzo, María T. Bourlon, André Sasse, Matteo Santoni, Shilpa Gupta, Francesco Massari,

Cancer Immunotherapy and Biomarkers

Combinations of immune checkpoint inhibitors (ICI) with platinum-based chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with metastatic urothelial carcinoma (mUC) have mixed results. Records were searched electronically from January 2019 to January 2024. A meta-analysis was performed to evaluate OS, progression-free survival (PFS), and overall response rate (ORR). Immune-based combinations were associated with an OS (HR: 0.75; 95% CI: 0.61–0.92; p < 0.001; I2= 84.1%) and PFS benefit in the intention-to-treat population (HR: 0.67; 95%CI: 0.51–0.89; p < 0.001; I2 = 89.7%). There was no ORR improvement with immune-based combinations (HR: 1.36; 95% CI:0.84–2.20; p < 0.001; I2 = 92.6%). This systematic review and study-level meta-analysis demonstrated that the immune-based combinations in first-line treatment for patients with mUC are associated with survival benefit.